Effects of dietary factors on levodopa pharmacokinetics

Bibliography

• Olanow CW. The pathogenesis of cell death in Parkinson's disease. Mov Disord 2007;22(Suppl 17):S335-42
   PubMedGoogle Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson´s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895-9
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. L-dopa in Parkinson's syndrome. N Engl J Med 1969a;281:272
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism–chronic treatment with L-dopa. N Engl J Med 1969b;280:337-45
   PubMed Web of Science ®Google Scholar
• Leiva C. Más de 20 años de Madopar. Rev Neurol 1997;25:1957-63
   PubMedGoogle Scholar
• Cotzias GC, van Woert MH, Schiffer L. Aromatic amino acids and modification of parkinsonism. N Eng J Med 1967;276:374-91
   PubMed Web of Science ®Google Scholar
• Rajput AH, Uitti RJ, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson´s disease. Parkinsonism Relat Disord 1997;3:159-65
   PubMedGoogle Scholar
• LeWitt PA, Taylor DC. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 2008a;5:210-25
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008b;359:2468-76
   PubMed Web of Science ®Google Scholar
• Linazasoro G. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Arch Neurol 2007;64:137-40
   PubMed Web of Science ®Google Scholar
• Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 2007;24:791-802
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frecuency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sidney Multicenter Study of Parkinson's disease: non- L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
   PubMed Web of Science ®Google Scholar
• Rivera-Calimlim L, Morgan JP, Dujovne CA, L-dopa absorption and metabolism by the human stomach. J Clin Invest 1970a;49:79a
   Web of Science ®Google Scholar
• Rivera-Calimlim L, Dujovne CA, Morgan JP, L-dopa treatment failure: explanation and correction. Br Med J 1970b;10:93-4
   Google Scholar
• Wade DN, Mearrick PT, Birkett DJ, Morris J. Variability of L-dopa absorption in man. Aust NZ J Med 1974;4:138-43
   PubMedGoogle Scholar
• Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-9
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-71
   PubMed Web of Science ®Google Scholar
• Grahnen A, Eckernas SA, Collin C, Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur Neurol 1992;32:343-8
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brogden RN, Sawyer PR, Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976;11:329-77
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-78
   PubMed Web of Science ®Google Scholar
• Wilding IR, Hardy JG, Davis SS, Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 1991;14:305-21
   PubMed Web of Science ®Google Scholar
• Jonkers N, Sarre S, Ebinger G, Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum. J Neural Transm 2001;108:559-70
   PubMed Web of Science ®Google Scholar
• Müller T. Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Pref Adher 2009;3:1-9
   PubMedGoogle Scholar
• Müller T, Woitalla D, Goetze O, Erdmann C. Entacapone improves absorption of a co-administered salt in patients with Parkinson's disease. Mov Disord 2008;23(10):1458-61
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113(10):1441-8
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006;21(3):332-6
   PubMed Web of Science ®Google Scholar
• Müller T, Kolf K, Ander L, Comparison of 200 mg retarded release levodopa/carbidopa–with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 2007;114(11):1457-62
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D, Impact of gastric emptying on levodopa pharmacokinetics in Parkinson's disease patients. Clin Neuropharmacol 2006;29(2):61-7
   PubMed Web of Science ®Google Scholar
• Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-8
   PubMed Web of Science ®Google Scholar
• Kempster PA, Frankel JP, Bovingdon M, Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-23
   PubMed Web of Science ®Google Scholar
• Deleu D, Sarre S, Ebinger G, Michotte Y. In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1991;344:514-9
   PubMed Web of Science ®Google Scholar
• Castro A, Valldeoriola F, Linazasoro G, Optimizacion del uso de la levodopa en la enfermedad de Parkinson: papel de la combinacion levodopa-carbidopa-entacapona. Neurologia 2005;20:180-8
   PubMedGoogle Scholar
• Woitalla D, Goetze O, Kim JI, Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006;253(9):1221-6
   PubMed Web of Science ®Google Scholar
• Muhlack S, Woitalla D, Welnic J, Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004;363:284-7
   PubMed Web of Science ®Google Scholar
• Van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs 2003;17:475-89
   PubMed Web of Science ®Google Scholar
• Garcia JJ, Fernandez N, Carriedo D, Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. Eur Neuropsychopharmacol 2005;15:497-503
   PubMed Web of Science ®Google Scholar
• Fernandez N, Carriedo D, Sierra M, Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa. Eur Neuropsychopharmcol 2005;15:505-9
   PubMed Web of Science ®Google Scholar
• Diez MJ, Garcia JJ, Prieto C, The hydrosoluble fiber Plantago ovata husk improves levodopa (with carbidopa) bioavailability after repeated administration. J Neurol Sci 2008;271:15-20
   PubMed Web of Science ®Google Scholar
• Özge A, Bugdayci R, Togrol E, Saracoglu M. The relation of gastrointestinal symptoms to duration of levodopa treatment and severity of Parkinson's disease. J Appl Res 2003;3:349-55
   Google Scholar
• Singaran C, Ashraf W, Gaumnitz EA, Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-4
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, Constipation in Parkinson´s disease: objetive assessment and response to psyllium. Mov Disord 1997;12:946-51
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Constipation in Parkinson´s disease. Klin Wochenschr 1991;69:906-9
   PubMedGoogle Scholar
• Abbott RD, Ross GW, White LR, Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003;3:III30-9
   Google Scholar
• Byrne KG, Pfeiffer R, Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center. J Clin Gastroenterol 1994;19:11-6
   PubMed Web of Science ®Google Scholar
• Edwards LE, Pfeiffer RF, Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726-32
   PubMed Web of Science ®Google Scholar
• Edwards LL, Pfeifer RF, Quigley EMM, Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151-6
   PubMed Web of Science ®Google Scholar
• Hardoff R, Saula M, Tamir A, Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-7
   PubMed Web of Science ®Google Scholar
• Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2004;100:232-44
   Web of Science ®Google Scholar
• Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease. Semin Neurol 1996;16:245-50
   PubMed Web of Science ®Google Scholar
• Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 1998;50:S11-4
   PubMed Web of Science ®Google Scholar
• McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985;80:1008-16
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997;12:952-7
   PubMed Web of Science ®Google Scholar
• Lesser J, Bateman DN. Domperidone. Br Med J 1985;290:241
   Web of Science ®Google Scholar
• Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52 http://adisonline.com/drugs/pages/issuelist.aspx
   PubMed Web of Science ®Google Scholar
• Neira WD, Sanchez V, Mena MA, de Yebenes JG. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995;10:66-70
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Koren M, Ziv I, Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-4
   PubMed Web of Science ®Google Scholar
• Voderholzer WA, Schatke W, Muhldorfer BE, Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997;92(1):95-8
   PubMed Web of Science ®Google Scholar
• Badiali D, Corzziari E, Habib FI, Effect of wheat bran in the treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci 1995;40:349-56
   PubMed Web of Science ®Google Scholar
• Fermaglich J, O'Doherty DS. Effect of gastric motility on levodopa. Dis Nerv Syst 1972;33:624-5
   PubMedGoogle Scholar
• Benini L, Castellani G, Brighenti F, Gastric emptying of a solid meal is accelerated by the removal of dietary fiber naturally presented in food. Gut 1995;36:825-30
   PubMed Web of Science ®Google Scholar
• Harju E, Heikkila J, Larmi TK. Effect of guar gum on gastric emptying after gastric resection. J Parenter Enternal Nutr 1984;8:18-20
   PubMed Web of Science ®Google Scholar
• Schonfeld J, Evans DF, Wingate DL. Effect of viscous fiber (guar) on postprandial motor activity in human small bowel. Dig Dis Sci 1997;42:1613-7
   PubMed Web of Science ®Google Scholar
• Bergmann JF, Chassany O, Petit A, Correlation between echographic gastric emptying and appetite. Influence of psyllium. Gut 1992;33:1042-3
   PubMed Web of Science ®Google Scholar
• Astarloa R, Mena MA, Sanchez V, Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
   PubMed Web of Science ®Google Scholar
• García JJ, Fernández N, Calle AP, Effects of Plantago ovata husk on levodopa (with carbidopa) bioavailability in rabbits with autonomic gastrointestinal disorders. Drug Metab Dispos 2009;37:1434-42
   PubMed Web of Science ®Google Scholar
• Russell J, Bass P. Canine gastric emptying of fiber meals: influence of meal viscosity and antroduodenal motility. Am J Physiol 1985;249:G662-667
   PubMed Web of Science ®Google Scholar
• Bianchi M, Capurso L. Effects of guar gum ispaghula and microcrystalline cellulose on abdominal symptoms gastric emptying orocaecal transit time and gas production in healthy volunteers. Dig Liver Dis 2002;34:S129-33
   PubMedGoogle Scholar
• Frost GS, Brynes AE, Dhillo WS, The effects of fiber enrichment of pasta and fat content on gastric emptying GLP-1 glucose and insulin responses to a meal. Eur J Clin Nutr 2003;57:293-8
   PubMed Web of Science ®Google Scholar
• Rigaud D, Paycha F, Meulemans A, Effect of psyllium on gastric emptying hunger feeling and food intake in normal volunteers: a double blind study. Eur J Clin Nutr 1998;52:239-45
   PubMed Web of Science ®Google Scholar
• Fernández N, Diez MJ, Terán MT, Influence of two commercial fibers in the pharmacokinetics of ethinilestradiol in rabbits. J Pharm Exp Ther 1998;286:870-4
   PubMed Web of Science ®Google Scholar
• García JJ, Fernández N, Diez MJ, Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol. Contraception 2000;62:253-7
   PubMed Web of Science ®Google Scholar
• Andersson I, Granerus AK, Jagenburg R, Svanborg A. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake. Acta Med Scand 1975;198:415-20
   PubMed Web of Science ®Google Scholar
• Leng-Peschlow E. Plantago ovata seeds as dietary fibre supplement physiological and metabolic effects in rats. Br J Nutr 1991;66:331-49
   PubMed Web of Science ®Google Scholar
• Isaksson G, Lundquist I, Ihse I. Effect of dietary fiber on pancreatic enzyme activity in vitro. Gastroenterology 1982;82:918-24
   PubMed Web of Science ®Google Scholar
• Leng-Peschlow E. Interference of dietary fibres with gastrointestinal enzymes in vitro. Digestion 1989;44:200-10
   PubMed Web of Science ®Google Scholar
• Hansen WE. Effect of dietary fiber on proteolytic pancreatic enzymes in vitro. Int J Pancreatol 1986;1:341-51
   PubMedGoogle Scholar
• Lennernäs H, Nilsson D, Aquilonius SM, The effect of L-leucine on the absorption of levodopa studied by regional jejunal perfusion in man. Br J Clin Pharmacol 1993;35:243-50
   PubMed Web of Science ®Google Scholar
• Nilsson D, Fagerholm U, Lennernas H. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharm Res 1994;11:1540-7
   PubMed Web of Science ®Google Scholar
• Carter JH, Nutt JG, Woodward WR, Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1989;39:552-6
   PubMed Web of Science ®Google Scholar
• Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975;292:181-4
   PubMed Web of Science ®Google Scholar
• Tsui JK, Ross S, Poulin K, The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology 1989;39:549-52
   PubMed Web of Science ®Google Scholar
• Robertson DR, Higginson I, Macklin BS, The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991;31:413-7
   PubMed Web of Science ®Google Scholar
• Karstaedt PJ, Pincus JH, Coughlin SS. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. Arch Neurol 1991;48:402-5
   PubMed Web of Science ®Google Scholar
• Bracco F, Malesani R, Saladini M, Battistin L. Protein redistribution diet and antiparkinsonian response to levodopa. Eur Neurol 1991;31:68-71
   PubMed Web of Science ®Google Scholar
• Sanchís G, Mena MA, Martín del Río R, Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease. Arch Neurobiol (Madr) 1991;54:296-302
   PubMedGoogle Scholar
• Nutt JG, Woodward WR, Hammerstad JP, The “on-off” phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8
   PubMed Web of Science ®Google Scholar
• Frankel JP, Kempster PA, Bovingdon M, The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989;52:1063-7
   PubMed Web of Science ®Google Scholar
• Simon N, Gantcheva R, Bruguerolle B, Viallet F. The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease. Parkinsonism Relat Disord 2004;10(3):137-42
   PubMed Web of Science ®Google Scholar
• Leenders KL, Poewe WH, Palmer AJ, Inhibition of L-[18F] fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20(2):258-62
   PubMed Web of Science ®Google Scholar
• Ogo Y, Sunagane N, Ohta T, Uruno T. Banana juice reduces bioavailability of levodopa preparation. Yakugaku Zasshi 2005;125(12):1009-11
   PubMed Web of Science ®Google Scholar
• Sunagane N, Aikawa M, Ohta T, Uruno T. Possibility of interactions between prescription drugs and OTC drugs (2nd report)–interaction between levodopa preparation and OTC Kampo medicines for upset stomach. Yakugaku Zasshi 2006;126(11):1191-6
   PubMed Web of Science ®Google Scholar
• Baruzzi A, Contin M, Riva R, Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-37
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release in parkinsonian patients. Eur J Clin Pharmacol 1998;54:303-8
   PubMed Web of Science ®Google Scholar
• Crevoisier C, Zerr P, Calvi-Gries F, Nilsen T. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm 2003;55:71-6
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Gorospe A. Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid. Neurologia 1995;10(6):220-3
   PubMedGoogle Scholar
• Nagayama H, Hamamoto M, Ueda M, The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 2004;27(6):270-3
   PubMed Web of Science ®Google Scholar
• Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23:S580-4
   PubMed Web of Science ®Google Scholar
• Abbruzzese G. Optimising levodopa therapy. Neurol Sci 2008;29:S377-9
   PubMed Web of Science ®Google Scholar
• Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2(3):234-43
   PubMedGoogle Scholar
• Ogawa N. Factors affecting levodopa effects in Parkinson's disease. Acta Med Okayama 2000;54(3):95-101
   PubMed Web of Science ®Google Scholar
• Marras C, Lang AE. Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74(2):143-6
   PubMed Web of Science ®Google Scholar
• Zappia M, Nicoletti A, Muñoz-S D, Tapia-Núñez J. Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence. Rev Neurol 2009;49(1):33-40
   PubMed Web of Science ®Google Scholar
• Barbeau A. High-level levodopa therapy in Parkinson's disease: five years later. Trans Am Neurol Assoc 1974;99:160-3
   PubMedGoogle Scholar
• Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Exp Rev Neurother 2009;9(6):859-67
   PubMed Web of Science ®Google Scholar